Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Tandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Both groups used a Dexcom G6 Continuous Glucose Monitoring (CGM ... The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ ...

New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions that older adults would ...

and integration with insulin pumps and digital health platforms. DexCom, Inc. (NASDAQ:DXCM) delivered strong performance in 2024 with revenue of $4.33 billion and organic growth of 12% ...

New research from Washington State University in collaboration with five other institutions suggests that automated insulin ...

Nearly 10% of postmarket device safety reports in MAUDE were submitted over 6 months after the safety event occurred.